Fig. 4

Molecular breast images in the mediolateral oblique projection from a 53-year-old patient with a palpable lesion that was suspicious on diagnostic mammography and scheduled for biopsy (Table 1, tumor #16). At blinded review, MBI performed with 300 MBq ^99mTc sestamibi (a) was interpreted as having moderate intensity radiotracer uptake in a segmental distribution with maximum extent of 11.0 cm. An assessment of 4 was assigned. MBI performed 1 day later with 300 MBq ^99mTc maraciclatide (b) was also interpreted as assessment 4 with lesion extent measuring 9.2 cm. Pathology revealed grade III invasive ductal carcinoma. Patient underwent subsequent neoadjuvant chemotherapy. Tumor extent measured on contrast-enhanced MRI prior to neoadjuvant chemotherapy was estimated at 9.2 cm